<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_indinavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:23:34 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Indinavir</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham, Pharm.D. and John G. Bartlett, M.D.</author>
<br>
<span class="display_date">03-24-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>
<B>Available formulation in Zambia: Capsule:</B> 200 mg; 333 mg; 400 mg (as sulfate). </li>
<li>Inferior to <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>-based regimen due to higher drop out rate </li>
<li>Rates of IDV-induced nephrolithiasis may be higher in warm climate countries. Pts should be encouraged to take adequate oral hydration. </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm.D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV infection in combination with other antiretrovirals. </li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Crixivan</I>
          </TD><TD valign="top">Indinavir sulfate (IDV)</TD><TD valign="top">Merck</TD><TD>oral</TD><TD>capsule</TD><TD>100 mg</TD><TD>$0.76</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral</TD><TD>capsule</TD><TD>200 mg</TD><TD>$1.52</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral</TD><TD>capsule</TD><TD>333 mg</TD><TD>$2.53</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral</TD><TD>capsule</TD><TD>400 mg</TD><TD>$3.03</TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>Pill burden: 8 caps per day (based on IDV 1000 mg + RTV 100 mg bid using 333 mg caps)<br>
<br>
<ul>
<li>IDV 800 mg q8h on an empty stomach or with a light snack (<U>&gt;</U>1 hac&nbsp;and&nbsp;<U>&gt;</U>2 hrs pc). Food restrictions apply to all unboosted IDV regimens below.</li>
<li>With <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (preferred): IDV 800 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100mg bid with or w/o food (higher rate of nephrotoxicity) or IDV 400 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV </A>400 mg bid with or w/o food (higher rate of GI side effects).</li>
<li>With <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>: IDV 1000 mg q8h + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs or IDV 800 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg bid with or w/o food + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs. </li>
<li>With <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>: IDV 1200 mg bid + <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> 1250 mg bid (rarely used; limited data).</li>
<li>With APV: IDV 800 mg q8h + APV 800 mg tid (rarely used; limited data).</li>
<li>With <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>: IDV 600 mg or 666 mg bid + <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> 400/100 mg bid.</li>
<li>With<A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124"> DLV</A>: IDV 600 mg q8h + <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> 400 mg tid.</li>
<li>With <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>: IDV 1000 mg q8h + <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> 200 mg bid or IDV 800 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg bid + <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> standard dose.</li>
<li>Not recommended with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>&nbsp;(due to potential for additive hyperbilirubinemia and <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> (due to <I>in vitro</I> antagonism).</li>
<li>FPV: no data. </li>
<li>TPV: no data. Avoid co-administration. </li>
<li>DRV: Dose not established. May increase risk of nephrolithiasis. </li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>Usual dose. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>Usual dose likely HD. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>Usual dose likely (pharmacokinetics unchanged in renal failure). <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>Usual dose. Very small amount removed in HD. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>No data: usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data. <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>
<ul>
<li>GI intolerance: <A class="headLines" target="_new" href="../../diagnosis/organ_system/nausea_vomiting1649.html?contentInstanceId=432759">nausea, vomiting</A>, and <A class="headLines" target="_new" href="../../diagnosis/organ_system/diarrhea8e47.html?contentInstanceId=432753">diarrhea</A>.</li>
<li>
<U>&gt;</U>2 retinoid-like side-effects (alopecia, dry skin, mouth, and eyes) in up to 30%; paronychia in 4-9%.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>Nephrolithiasis +/- hematuria: 5-20% (highest risk with IDV 800 mg bid +<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950"> RTV</A> 100-200 mg bid, lowest risk with IDV 400 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 400 mg bid). Encourage adequate oral hydration.</li>
<li>Indirect hyperbilirubinemia (<U>&gt;</U>2.5 mg/dL in 10-15% of pts but clinically insignificant).</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">Lipodystrophy</A>, especially fat accumulation or gynecomastia.</li>
<li>Insulin resistance +/- hyperglycemia +/- diabetes.</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hyperlipidemia4edb.html?contentInstanceId=434827">Hyperlipidemia</A>: increased triglycerides and/or cholesterol. </li>
<li>Increased&nbsp;transaminases.</li>
<li>Nephropathy: sterile leukocyturia, erythrocyturia, IDV crystalluria, and albumin loss (35% with increased serum creatinine). </li>
<li>Interstitial nephritis with pyuria and renal insufficiency reported in 2% (<A class="headLines" target="_new" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=11915002&amp;dopt=abstract"><I>Clin Infect Dis </I>2002;34:1122</A>).</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>Pruritis and rash. </li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>Substrate and inhibitor of CYP3A4 and weak inhibitor of CYP2D6. May increase levels of CYP3A4 (and possibly 2D6) substrates. CYP3A4 inhibitors and inducers may increase and decrease IDV levels, respectively. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">Delavirdine</A>
          </B></TD><TD valign="top">IDV AUC: increased by 44% (compared to 800 mg q8h).</TD><TD valign="top">Recommended dose: decrease IDV to 600 mg q8h + <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> 400 mg tid.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">Efavirenz (EFV)</A>
          </B></TD><TD valign="top">IDV AUC: decreased by 31-35%; <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>: no effect.</TD><TD valign="top">Recommended dosing: IDV 1000 mg q8H + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs or IDV 800 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg bid + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/fluconazoled462.html?contentInstanceId=434183">Fluconazole</A>
          </B></TD><TD valign="top">No significant interaction</TD><TD valign="top">Use standard dose of both drugs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>
          </B></TD><TD valign="top">IDV AUC increased by 20%, Cmin increased by 46%;&nbsp;IDV Cmin increased by 247%; LPV no change.</TD><TD valign="top">Dose: IDV 600 mg or 666 mg bid + <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> 400/100 mg bid.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">Nevirapine</A>
          </B></TD><TD valign="top">No effect on <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>; Decrease IDV AUC by 28%. </TD><TD valign="top">IDV 1000 mg q8h + <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> 200 mg bid or IDV 800 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg bid + <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> standard dose. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">Nelfinavir</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> AUC: increased by 83%.</TD><TD valign="top">Dose: IDV 1200 mg bid + <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> 1250 bid (limited clinical data).</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">Rifampin</A>
          </B></TD><TD valign="top">IDV AUC decreased by 89%.</TD><TD valign="top">Do not co-administer IDV (even with the addition of <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>). </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">Ritonavir</A>
          </B></TD><TD valign="top">IDV Cmin increased by 10-fold (dose: IDV 800 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg bid compared to IDV 800 mg q8h).</TD><TD valign="top">Dose: IDV800 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg bid (high rate of nephrotoxicity) or I, or IDV 400 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 400 mg bid (high rate of GI toxicity).</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">Saquinavir</A>
          </B></TD><TD valign="top">Increase <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> AUC by 4-7 fold; No effect on IDV. </TD><TD valign="top">No data. Possible <I>in vitro </I>antagonism.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI </A>(buffered)</B></TD><TD valign="top">IDV AUC decreased by 84%.</TD><TD valign="top">Administer IDV 1hr before or after <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A>(buffered). Consider using <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI </A>EC since there are no interactions with IDV.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Alprazolam
          </B></TD><TD valign="top">May increase serum levels of alprazolam.</TD><TD valign="top">Consider an alternative benzodiazepine (lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Amiodarone</B></TD><TD valign="top">In a case report amiodarone levels increased by 44%.</TD><TD valign="top">Contraindicated. Monitor for amiodarone toxicity. Consider alternative antiarrhythmic with cardiology consult.</TD>
</TR>
<TR>
<TD valign="top"><B>Amlodipine</B></TD><TD valign="top">May increase serum levels of amlodipine.</TD><TD valign="top">Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging the PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Amprenavir
          </B></TD><TD valign="top">APV clearance decreased by 54% APV AUC: increased by 33%; Cmin: increased by 25%; IDV AUC decreased by 38%.</TD><TD valign="top">Data based on PK modeling with many confounding variables (i.e. <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV </A>in the background regimen). Consider IDV 800 mg q8h + APV 800 mg tid (limited data).</TD>
</TR>
<TR>
<TD valign="top"><B>Artemether (artemisinin)</B></TD><TD valign="top">May increase serum levels of artemether.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Close monitoring for artemether toxicity (bone marrow suppression, bradycardia, and seizure).</TD>
</TR>
<TR>
<TD valign="top"><B>Astemizole</B></TD><TD valign="top">May significantly increase astemizole serum levels.</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmias. Recommended alternative antihistamine: loratadine, fexofenadine, desloratidine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Atorvastatin
          </B></TD><TD valign="top">May increase atorvastatin levels.</TD><TD valign="top">Avoid combination. Consider alternative agents: pravastatin, fluvastatin, or rosuvastatin. With co-administration, use low dose atorvastatin and monitor for ADRs due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Atovaquone
          </B></TD><TD valign="top">No significant interaction.</TD><TD valign="top">Use standard dose of both drugs.</TD>
</TR>
<TR>
<TD valign="top"><B>Azathioprine</B></TD><TD valign="top">Interaction unlikely.</TD><TD valign="top">Use standard doses.</TD>
</TR>
<TR>
<TD valign="top"><B>Bepridil</B></TD><TD valign="top">May significantly increase bepridil serum levels.</TD><TD valign="top">No data. Manufacturers of <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>, <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>, and APV do not recommend bepridil co-administration; this contraindication should extend to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> since significant increase in bepridil serum levels can result in pro-arrhythmic events such as VT, PVC, and VF.</TD>
</TR>
<TR>
<TD valign="top"><B>Carbamazepine</B></TD><TD valign="top">IDV levels: decreased 4-25% of mean population values.</TD><TD valign="top">Consider alternative anticonvulsants (i.e valproic acid, lamotrigine, levetiracetam, or topiramate). With co-administration, monitor anticonvulsants levels and consider TDM of IDV.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Chlordiazepoxide
          </B></TD><TD valign="top">May increase serum levels of chlordiazepoxide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider an alternative benzodiazepine ( lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Cisapride</B></TD><TD valign="top">May significantly increase cisapride serum levels.</TD><TD valign="top">Contraindicated due to potential for cardiac arrhythmias. Recommended alternative: metoclopramide.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Clorazepate
          </B></TD><TD valign="top">May increase serum levels of clorazepate.</TD><TD valign="top">Applies to all PIs and DLV: Consider an alternative benzodiazepine (lorazepam, oxazepam, or temazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclophosphamide</B></TD><TD valign="top">Cyclophosphamide: clearance decreased by 1.5 fold; IDV: no change.</TD><TD valign="top">Clinical significance unknown. May require cyclophosphamide dose adjustment.</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclosporine</B></TD><TD valign="top">May significantly increase serum levels of cyclosporine.</TD><TD valign="top">Applies to all PIs: Monitor serum levels of cyclosporine closely with co- administration. Cyclosporine dose may need to be decreased.</TD>
</TR>
<TR>
<TD valign="top"><B>Darunavir </B></TD><TD valign="top">IDV AUC and Cmin increased 23% and 125%, respectively. DRV AUC and Cmin increased 24% and 44%, respectively. </TD><TD valign="top">Dose not established. May increase risk of nephrolithiasis. </TD>
</TR>
<TR>
<TD valign="top"><B>Digoxin </B></TD><TD valign="top">Digoxin serum concentration may be increased with IDV/r co-administration. </TD><TD valign="top">Monitor digoxin serum concentration closely with co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Diltiazem</B></TD><TD valign="top">May increase serum levels of diltiazem.</TD><TD valign="top">Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging PR interval with diltiazem co-administration. Diltiazem should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Disopyramide</B></TD><TD valign="top">May increase disopyramide serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Monitor disopyramide serum levels (target: 2 to 7.5 mcg/mL).</TD>
</TR>
<TR>
<TD valign="top"><B>Docetaxel</B></TD><TD valign="top">May increase serum levels of docetaxel.</TD><TD valign="top">Applies to all PIs and DLV: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Dofetilide</B></TD><TD valign="top">May significantly increase dofetilide levels.</TD><TD valign="top">No data. Use with caution. Monitor QTc closely and adjust dofetilide dosing based on QTc prolongation and renal function. Consider an alternative class III antiarrhythmic such as bretylium or ibutilide.</TD>
</TR>
<TR>
<TD valign="top"><B>Doxorubicin</B></TD><TD valign="top">Doxorubicin: no change in clearance; IDV: no change.</TD><TD valign="top">Use standard dose. Close monitoring recommended due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Dronabinol
          </B></TD><TD valign="top">No significant interaction.</TD><TD valign="top">Use standard doses of both drugs.</TD>
</TR>
<TR>
<TD valign="top"><B>Echinacea </B></TD><TD valign="top">May decrease IDV serum level. Echinacea (400 mg 4x/d) decreased CYP3A4 substrate (midazolam) by 23%.</TD><TD valign="top">Applies to all PIs and NNRTIs. Clinical significance unknown but should avoided until the safety of this combination is further evaluated.</TD>
</TR>
<TR>
<TD valign="top"><B>Ergot alkaloids</B></TD><TD valign="top">May significantly increase ergotamine levels. Case report of ergotism has been reported.</TD><TD valign="top">Contraindicated. Consider alternative agent for migraine such as sumatriptan (but not eletriptan since it is a CYP3A4 substrate and significant drug-drug interaction occurred with CYP3A4 inhibitor).</TD>
</TR>
<TR>
<TD valign="top"><B>Estazolam</B></TD><TD valign="top">May increase serum levels of estazolam.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider an alternative benzodiazepine (lorazepam, oxazepam, or temazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Ethosuximide</B></TD><TD valign="top">May increase serum levels of ethosuximide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider switching to valproic acid for the treatment of absence seizure.</TD>
</TR>
<TR>
<TD valign="top"><B>Etoposide</B></TD><TD valign="top">May increase serum levels of etoposide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Felodipine</B></TD><TD valign="top">May increase serum levels of felodipine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led PR interval prolongation). All PIs and<A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124"> DLV</A> have the potential of prolonging PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Fentanyl
          </B></TD><TD valign="top">May significantly increase serum levels of fentanyl.<BR>.</TD><TD valign="top">Use with caution. Consider morphine.</TD>
</TR>
<TR>
<TD valign="top"><B>Flecainide</B></TD><TD valign="top">May increase antiarrhythmic serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Avoid co-administration; if necessary, monitor flecainide trough levels with co-administration. Target: 200-1000 ng/mL. Toxicity is frequent with trough serum levels above 1000 ng/mL.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Flurazepam
          </B></TD><TD valign="top">May increase serum levels of flurazepam.</TD><TD valign="top">Applies to all PIs and DLV: Consider an alternative benzodiazepine (lorazepam, oxazepam, or temazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Fluticasone </B></TD><TD valign="top">Fluticasone serum concentration may be increased with IDV/r co-administration. </TD><TD valign="top">Avoid long term co-administration. Consider beclomethasone. </TD>
</TR>
<TR>
<TD valign="top"><B>Food</B></TD><TD valign="top">IDV AUC decreased by 77% with a 784 kcal meal (48.6 g fat, 31.3 g protein). IDV not significantly affected by a light meal (toast and jelly, apple juice, coffee with skim milk and sugar or a meal of corn flakes).</TD><TD valign="top">Take on an empty stomach or with light snack <U>&gt;</U>1 hr ac and <U>&gt;</U>2 hrs pc when IDV given as the sole&nbsp;PI. IDV co-administered with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (IDV 800 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg bid) removes food effect and is preferred.</TD>
</TR>
<TR>
<TD valign="top"><B>Garlic Supplements</B></TD><TD valign="top">Studies only done with <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> and revealed 49% and 51% reduction of <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> Cmin and AUC, respectively when co-administered with garlic supplement (3.5 grams bid). </TD><TD valign="top">Unknown interaction with other PIs. Studies only done with <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> but garlic supplement may affect serum levels of other PIs and NNRTIs. Avoid co-administration with PIs and NNRTIs. </TD>
</TR>
<TR>
<TD valign="top"><B>Granisetron</B></TD><TD valign="top">May increase serum levels of granisetron.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Due to the large therapeutic index of granisetron, potential interaction is unlikely to be clinically significant.</TD>
</TR>
<TR>
<TD valign="top"><B>Grape fruit or Seville orange juice</B></TD><TD valign="top">No significant interaction. IDV AUC decreased by 26%. </TD><TD valign="top">Clinically significant interaction unlikely. Studies conducted with unboosted IDV. Clinical significance unknown but boosting IDV with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (IDV 800 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg bid) will likely overcome any potential interaction.</TD>
</TR>
<TR>
<TD valign="top"><B>Heroin (Diamorphine)</B></TD><TD valign="top">Drug interactions unlikely.</TD><TD valign="top">Applies to PIs and NNRTIs: Interaction unlikely but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Ifosphamide</B></TD><TD valign="top">May increase serum levels of ifosphamide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Irinoteacan</B></TD><TD valign="top">May increase irinotecan serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Co-administration of ATV is contraindicated by manufacturer. All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> also have the potential for significant interaction with Irinotecan, therefore the co-administration should be done with extreme caution.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Itraconazole
          </B></TD><TD valign="top">IDV serum levels may be increased by itraconazole.</TD><TD valign="top">Dose: IDV 600 mg q8h. When co-administered with itraconazole, IDV 600 mg q8h has equivalent PK&nbsp;compared to IDV 800 mg q8h. Do not exceed itraconazole 200 mg bid. No data with IDV/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> co-administration. Consider IDV 800 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100mg bid with aggressive hydration due to the potential increased risk of nephrolithiasis.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Ketoconazole
          </B></TD><TD valign="top">IDV AUC: increased by 68%.</TD><TD valign="top">Dose: IDV to 600 mg q8h. Consider IDV 800 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg bid (do not exceed ketoconazole 200 mg/d) with aggressive hydration due to potential increased risk of nephrolithiasis.</TD>
</TR>
<TR>
<TD valign="top"><B>Lidocaine</B></TD><TD valign="top">May increase antiarrhythmic serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Use with caution, monitor lidocaine serum levels (target: 1.5 to 6 mcg/mL) with co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Lovastatin</B></TD><TD valign="top">May significantly increase lovastatin levels.</TD><TD valign="top">Contraindicated. Recommended alternatives include pravastatin, rosuvastatin, or fluvastatin. Monitor for ADRs due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>Mefloquine</B></TD><TD valign="top">May increase serum levels of mefloquine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Monitor mefloquine serum levels and for mefloquine toxicity (i.e dizziness, LFTs, and periodic ophthalmic examination).</TD>
</TR>
<TR>
<TD valign="top"><B>Methadone</B></TD><TD valign="top">No change in methadone or IDV serum levels. </TD><TD valign="top">No interaction. Use standard dose of both drugs.</TD>
</TR>
<TR>
<TD valign="top"><B>Mexiletine</B></TD><TD valign="top">May increase antiarrhythmic serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Use with caution. Monitor EKG and serum levels. Serum levels exceeding 1.5 to 2 mcg/mL have been associated with an increased risk of toxicity.</TD>
</TR>
<TR>
<TD valign="top"><B>Midazolam</B></TD><TD valign="top">May significantly increase midazolam levels.</TD><TD valign="top">Concurrent administration contraindicated due to potential for prolonged sedation. Consider alternative benzodiazepines (lorazepam, oxazepam, or temazepam). Single dose midazolam may be used (chronic use not recommended).</TD>
</TR>
<TR>
<TD valign="top"><B>Milk thistle (silymarin)</B></TD><TD valign="top">IDV AUC: unchanged IDV Cmin: decreased by 25%.</TD><TD valign="top">Clinical significance unknown. Since milk thistle has not shown clinical benefit for the treatment of viral hepatitis, avoid co-administration with IDV until it can be further evaluated.</TD>
</TR>
<TR>
<TD valign="top"><B>Mirtazapine</B></TD><TD valign="top">May increase serum levels of mirtazapine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine).</TD>
</TR>
<TR>
<TD valign="top"><B>Mycophenolate</B></TD><TD valign="top">Interaction unlikely. No significant interaction observed with <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>.</TD><TD valign="top">Applies to all PIs and NNRTIs: No significant interaction observed with <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Nefazodone</B></TD><TD valign="top">May increase serum levels of nefazodone.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine).</TD>
</TR>
<TR>
<TD valign="top"><B>Nifedipine</B></TD><TD valign="top">May increase serum levels of nifedipine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging the PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Nisoldipine</B></TD><TD valign="top">May increase serum levels of nisoldipine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging the PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Norethindrone and Ethinylestradiol</B></TD><TD valign="top">Norethindrone levels increased by 26% and Ethinylestradiol by 24%.</TD><TD valign="top">Use of barrier method of contraception is recommended to prevent pregnancy.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Paclitaxel
          </B></TD><TD valign="top">May increase paclitaxel serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to case reports of severe toxicity associated with <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> and <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> co-administration with paclitaxel. Since all PIs have the potential of significantly increasing paclitaxel serum levels, close monitoring of paclitaxel-induced toxicity is recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>PCP</B></TD><TD valign="top">May significantly increase serum levels of PCP.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>. Avoid all illicit drug use with PIs and NNRTIs. </TD>
</TR>
<TR>
<TD valign="top"><B>Phenobarbital</B></TD><TD valign="top">May decrease IDV serum levels. PIs and NNRTIs may increase or decrease phenobarbital serum levels.</TD><TD valign="top">Applies to All PIs and NNRTIs: Consider alternative anticonvulsants (i.e valproic acid, lamotrigine, levetiracetam, or topiramate). With co-administration, monitor anticonvulsants levels and consider TDM of PIs and NNRTIs.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenytoin</B></TD><TD valign="top">May significantly decrease IDV serum levels.</TD><TD valign="top">Applies to all PIs and NNRTIs: Consider alternative anticonvulsants (i.e valproic acid, lamotrigine, levetiracetam, or topiramate). Monitor anticonvulsant levels and consider TDM of PIs and NNRTIs.</TD>
</TR>
<TR>
<TD valign="top"><B>Pimozide</B></TD><TD valign="top">May significantly increase pimozide serum levels resulting in QTc prolongation.</TD><TD valign="top">Contraindicated. Consider alternative: olanzapine.</TD>
</TR>
<TR>
<TD valign="top"><B>PPI (Omeprazole)</B></TD><TD valign="top">No significant interaction.</TD><TD valign="top">Use standard dose of both drugs.</TD>
</TR>
<TR>
<TD valign="top"><B>Prednisone </B></TD><TD valign="top">Prednisolone serum concentration may be increased with IDV/r co-administration. </TD><TD valign="top">Dose adjustment may be needed with long-term co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Propafenone</B></TD><TD valign="top">May significantly increase serum levels of propafenone.</TD><TD valign="top">Do not co-administer.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Quinidine
          </B></TD><TD valign="top">IDV AUC increased by 10%(NS) based on a single dose study. Quinidine serum levels not reported.</TD><TD valign="top">Manufacturer does not recommend dose adjustment; however, use with caution since this was a single dose study. Monitoring of EKG (QTc) and serum levels: Target: 2 to 5 mcg/mL.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifabutin(RFB)
          </B></TD><TD valign="top">Rifabutin AUC increased by 204%; IDV AUC decreased by 32%.</TD><TD valign="top">Recommended dose: RFB 150 mg qd (or 300 mg 3x/wk) + IDV 1000 mg q8h or RFB 150 mg qod (or 150 mg 3x/wk) + IDV 800 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg bid (recommended but no data).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifapentine
          </B></TD><TD valign="top">IDV AUC decreased by 75%. Rifapentine AUC not affected.</TD><TD valign="top">Avoid co-administration. Consider using RFB.</TD>
</TR>
<TR>
<TD valign="top"><B>Rosuvastatin</B></TD><TD valign="top">Other CYP3A4 inhibitor (i.e <A class="headLines" target="_new" href="../antimicrobial_agents/erythromycin329b.html?contentInstanceId=434157">erythromycin</A>) did not affect rosuvastatin serum levels.</TD><TD valign="top">Applies to PIs and NNRTI: interaction unlikely, but close monitoring recommended due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>Sildenafil</B></TD><TD valign="top">May significantly increase sildenafil serum levels.</TD><TD valign="top">Use with caution. Do not exceed 25 mg of sildenafil in 48 hrs.</TD>
</TR>
<TR>
<TD valign="top"><B>Simvastatin</B></TD><TD valign="top">May significantly increase simvastatin levels.</TD><TD valign="top">Contraindicated. Recommended alternatives include atorvastatin, pravastatin, fluvastatin, and rosuvastatin. Monitor for adverse effects due to limited clinical data with these agents.</TD>
</TR>
<TR>
<TD valign="top"><B>Sirolimus</B></TD><TD valign="top">May significantly increase serum levels of sirolimus.</TD><TD valign="top">Applies to all PIs: Dose sirolimus based on serum level. A significant&nbsp;reduction in sirolimus dose when combined with any PI is likely to be necessary.</TD>
</TR>
<TR>
<TD valign="top"><B>St. John's wort</B></TD><TD valign="top">IDV AUC decreased by 57%.</TD><TD valign="top">Contraindicated with all PIs and NNRTIs. Use an alternative antidepressant.</TD>
</TR>
<TR>
<TD valign="top"><B>Tacrolimus</B></TD><TD valign="top">May significantly increase tacrolimus levels.</TD><TD valign="top">Dose tacrolimus based on serum levels. A significant reduction of tacrolimus dose with IDV co-administration is likely to be necessary.</TD>
</TR>
<TR>
<TD valign="top"><B>Tadalafil</B></TD><TD valign="top">May increase serum levels of tadalafil.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Start with 5 mg. Do not exceed 10 mg in 72 hrs. Consider sildenafil due to more clinical data and shorter half-life allowing for easier titration.</TD>
</TR>
<TR>
<TD valign="top"><B>Tamoxifen</B></TD><TD valign="top">May increase serum levels of tamoxifen.</TD><TD valign="top">Applies to all PIs and DLV: No data. Close monitoring of tamoxifen-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Teniposide</B></TD><TD valign="top">May increase serum levels of teniposide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of teniposide-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Terfenadine</B></TD><TD valign="top">May significantly increase terfenadine serum levels.</TD><TD valign="top">Removed from IDV contraindicated list since it is no longer available in the U.S. However, the potential of an old terfenadine bottle still poses a risk for cardiac arrhythmias with co-administration. Recommended alternative antihistamine: loratadine, fexofenadine, desloratidine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>THC</B></TD><TD valign="top">Based on data with <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV </A>and IDV interactions are unlikely.</TD><TD valign="top">Applies to PIs and NNRTIs: interactions are unlikely but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Tipranavir<BR>
</B></TD><TD valign="top">No data </TD><TD valign="top">Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Trazadone</B></TD><TD valign="top">May increase serum levels of trazadone.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider alternative antidepressants (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Triazolam
          </B></TD><TD valign="top">May significantly increase triazolam serum levels.</TD><TD valign="top">Concurrent administration contraindicated due to potential for prolonged sedation. Consider alternative benzodiazepines(lorazepam, oxazepamor temazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Vardenafil</B></TD><TD valign="top">Vardenafil AUC increased by 16-fold. IDV AUC decreased by 30%.</TD><TD valign="top">Do not exceed vardenafil 2.5 mg in 24 hrs. Consider sildenafil due to more clinical data and less pronounced interaction.</TD>
</TR>
<TR>
<TD valign="top"><B>Venlafaxine</B></TD><TD valign="top">IDV AUC decreased by 28%. Venlafaxine: no effect.</TD><TD valign="top">Clinical significance unknown. Small study PK that used unboosted IDV; the observed change may be within the PK variability of IDV. Consider alternative SSRI (i.e escitalopram).</TD>
</TR>
<TR>
<TD valign="top"><B>Verapamil</B></TD><TD valign="top">May increase serum levels of verapamil.</TD><TD valign="top">Applies to all PIs and DLV: Data limited to an interaction study conducted with ATV and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and DLV have the potential of prolonging the PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Vinblastine</B></TD><TD valign="top">May increase serum levels of vinblastine.</TD><TD valign="top">Applies to all PIs and DLV: No data. Close monitoring of vinblastine-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Vincristine</B></TD><TD valign="top">May increase serum levels of vincristine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of vincristine-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Vitamin C </B></TD><TD valign="top">IDV AUC decreased by 14% and Cmin by 32% when co-administered with vitamin C (1 mg/d).</TD><TD valign="top">Clinical significance unknown due to small sample size (n=7). Boosting IDV with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (IDV 800 mg bid + RTV 100 mg bid) will likely overcome this potential interaction. Unknown effect on the serum levels of other PIs and NNRTIs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Voriconazole
          </B></TD><TD valign="top">No significant change voriconazole and IDV AUC. Voriconazole serum concentration may be decreased with IDV/r.</TD><TD valign="top">No significant interaction with unboosted IDV. Use standard dose of both drugs.&nbsp;WIth IDV/r, monitor voriconazole serum concentration. </TD>
</TR>
<TR>
<TD valign="top"><B>Warfarin</B></TD><TD valign="top">Case report of increased INR.</TD><TD valign="top">Other PIs and NNRTIs may also affect warfarin requirements. Monitor INR closely with co-administration.</TD>
</TR>
</TABLE>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>V82A/T/F/S: Most common mutations with IDV monotherapy, results in intermediate IDV resistance and cross-resistance to other PIs. 82I does not cause PI resistance. Primary mutation (82A/F/T/S, 84V/A/C, 46I/L): Low to intermediate resistance with individual mutations, but significant IDV resistance with multiple mutations.</li>
<li>Other PI mutations: (10I/R/V, 20M/R, 24I, 32I, L33F, 36I, 46I/L, 54V, 71V/T, 73S/A, 77I, 84V/A/C, 90M): <U>&gt;</U>3 results in &gt;4-fold decrease in susceptibility.</li>
<li>
<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> boosting can increase activity against PI-resistant virus. </li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10F1B"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>Inhibition of HIV protease, which results in nonfunctional, immature and non-infectious virions.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                65% absorption in fasting state (food decreases absorption by 77%).</li>
<li>Metabolism and Excretion: 
                Metabolized by the CYP 3A4 to several hydroxylated metabolite, which undergo subsequent glucuronidation. Both unchanged drug and metabolites are excreted in the feces.</li>
<li>Protein Binding: 
                60% (variable).</li>
<li>Cmax, Cmin, and AUC: 
                Mean steady-state AUC=18.8 mcg hr/mL; Cmax=7.7 mcg/mL; Cmin=0.154 mcg/mL. Serum levels significantly decreased in pregnancy.</li>
<li>T1/2: 
                1.5-2 hrs.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>Use with caution in ESLD.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category C: Placental passage is significant in rats, but low in rabbits. Not teratogenic in rodent studies (but extra ribs have been reported). Incidence of hyperbilirubinemia in neonatal Rhesus monkeys approximately 4-fold above controls. No data on carcinogenicity. Dose not established, but should not be used without RTV boosting in pregnancy (FDA warning). Mean level decreased by 68% at 30-32 weeks gestation compared to 6 weeks postpartum. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>Unknown breast milk excretion. Breast feeding is not recommended in the U.S. in order to avoid post-natal transmission of HIV to the child, who may not yet be infected.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>
<ul>
<li>Pros: Long-term clinical data supporting durability and potency; multiple mutations required for resistance.</li>
<li>Cons: Variable PK and inconvenient dosing without <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> boosting; nephrolithiasis (unique to IDV); GI side effects; retinoid effects (unique to IDV); insulin resistance (more common than with other PIs). </li>
</ul>
<a name="N10F60"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Dragsted UB, Gerstoft J, Pedersen C, et al.;
		Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.;        
		J Infect Dis;
		2003; Vol. 
		188; pp. 
		635-42;
		<br>ISSN:
	        	0022-1899;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=12934178&amp;dopt=abstract" target="_new">12934178</a>
<br>
<b>Comments:</b>Open-label trial involving 306 pts randomized to receive IDV 800 mg bid + RTV 100 mg bid or <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> (sgc but allowed to change to hgc) 1000 mg bid + RTV 100 mg bid. At 48 wks, virological failure in 43 (27%) of 158 and 37 (25%) of 148 pts in IDV/RTV and SQV/RTV arms, respectively. More pts in IDV/RTV arm experienced ADRs. Failure seen in 78 of 158 pts in the ADV/RTV arm, vs. 51 of 148 in the SQV/RTV arm when switching from randomized treatment counted as failure(p=.009). <br>
<br>
</li>
<li>Shulman N, Zolopa A, Havlir D, et al.;
		Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.;        
		Antimicrob Agents Chemother;
		2002; Vol. 
		46; pp. 
		3907-16;
		<br>ISSN:
	        	0066-4804;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=12435695&amp;dopt=abstract" target="_new">12435695 </a>
<br>
<b>Comments:</b>This trial evaluated the effect of intensification with boosting with RTV. 37 HIV infected subjects with chronic detectable viremia and receiving 800 mg of IDV tid were switched to IDV 400 mg bid + RTV 400 mg bid for 48 wks. At wk 3, 58% (21 of 36) achieved VL&lt;50 l or a reduction from the baseline load of =0.5 log10 . <br>
<br>
</li>
<li>Staszewski S, Morales-Ramirez J, Tashima KT, et al.;
		Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.;        
		N Engl J Med;
		1999; Vol. 
		341; pp. 
		1865-73;
		<br>ISSN:
	        	0028-4793;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=10601505&amp;dopt=abstract" target="_new">10601505</a>
<br>
<b>Comments:</b>Open-label study involving 450 pts naive to <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">3TC</A>, NNRTIs, and PIs: randomized to receive <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">3TC</A>; IDV + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">3TC</A>, or <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> + IDV. At 48 wks, by ITT analysis, VL &lt;50 achieved in more pts in <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">3TC</A> arm than in IDV + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">3TC</A> arm (64% vs. 43%, p &lt;0.01). More pts discontinued treatment because of ADRs in IDV arm vs. <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> arm (43% vs. 27%, p=0.005).<br>
<br>
</li>
<li>Gulick RM, Mellors JW, Havlir D, et al.;
		Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.;        
		N Engl J Med;
		1997; Vol. 
		337; pp. 
		734-9;
		<br>ISSN:
	        	0028-4793;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=9287228&amp;dopt=abstract" target="_new">9287228 </a>
<br>
<b>Comments:</b>One of earliest HAART trials comparing IDV + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">3TC</A>, IDV monotherapy, and <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">3TC</A> in 97 pts who had received <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> for &gt;6 mos, had CD4 50-400, and VL &gt;20,000. Decrease in VL over the 1st 24 wks was greater in 3-drug arm than in the other arms (90% vs 43% vs 0%, respectively p &lt;0.001 for each comparison). In an open-label continuation with up to 6 yr follow-up, 47% of pts on IDV + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">3TC</A> arm maintained VL &lt;50 (<A class="headLines" target="_new" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=14571186&amp;dopt=abstract">Gulick RM, Meibohm A, Havlir D, et al. AIDS 2003;17:2345-9</A>).<br>
<br>
</li>
</ol>
<a name="REFERENCED WITHIN THIS GUIDE"></a>
<h2 class="grayLineHeaderBar">REFERENCED WITHIN THIS GUIDE</h2>
<ul>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/nausea_vomitingc4ac.html?contentInstanceId=432945&amp;siteId=429188">Nausea/Vomiting</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/nutrition_care_and_supportc4ac.html?contentInstanceId=432945&amp;siteId=429188">Nutrition Care and Support</A>
</li>
</ul>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_indinavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:23:34 GMT -->
</html>
